Silverberg, Jonathan I. http://orcid.org/0000-0003-3686-7805
Boguniewicz, Mark http://orcid.org/0000-0002-1015-4439
Hanifin, Jon
Papp, Kim A. http://orcid.org/0000-0001-9557-3642
Zhang, Haixin
Rossi, Ana B. http://orcid.org/0000-0001-5345-678X
Levit, Noah A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
https://doi.org/10.1007/s13555-021-00643-4
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
https://doi.org/10.1007/s13555-022-00822-x
Documents that mention this clinical trial
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
https://doi.org/10.1007/s13555-021-00643-4
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
https://doi.org/10.1007/s13555-022-00822-x
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 8 July 2022
Accepted: 21 September 2022
First Online: 21 October 2022